Associated Papers
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO).
Pizzutilo EG et al.
Esmo Open, 2024
Immunogenomic analysis of human brain metastases reveals diverse immune landscapes across genetically distinct tumors.
Álvarez-Prado ÁF et al.
Cell Reports. Medicine, 2023
36652909 (PubMed )
Supplement: mmc3.xlsx › BrM96
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
35304574 (PubMed )
Supplement: 41388_2022_2263_MOESM5_ESM.xlsx › Supplementary_Table_4
A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib.
Xing K et al.
Medical Oncology (northwood, London, England), 2014
Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
Liu Y et al.
International Journal of Clinical and Experimental Pathology, 2013
Epidermal growth factor receptor mutation in gastric cancer.
Liu Z et al.
Pathology, 2011
Detection of epidermal growth factor receptor variations by partially denaturing HPLC.
Chin TM et al.
Clinical Chemistry, 2007
Select a paper to view details